BioAge Labs, Inc. Common Stock (BIOA) Stock Price
BIOAStock
$9.65+101.04%52W
Market Cap$442.91M
P/E—
PEG Ratio—
Div yield—
Beta2.23
BIOA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-67.17%
Price vs S&P 500 (4W)-12.02%
VGM Score57.62
BIOA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.62 | -$0.58 | +7.09%(+$0.04) | |
| Q1 2026 | -$0.63 | -$0.52 | +17.13%(+$0.11) | |
| Q4 2025 | -$0.67 | -$0.72 | -7.69%(-$0.05) | |
| Q3 2025 | -$0.51 | -$0.56 | -9.02%(-$0.05) | |
| Q2 2025 | -$0.38 | -$0.60 | -57.31%(-$0.22) |
BIOA Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.15
4.20
4.20
4.20
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BIOABioAge Labs, Inc. Common Stock | C | A | C | $9.65 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About BioAge Labs, Inc. Common Stock
Bioage Labs is a clinical-stage biopharmaceutical company developing treatments for metabolic diseases like obesity by targeting the biology of aging. Its pipeline includes NLRP3 inhibitors and APJ agonists designed to address the underlying mechanisms of age-related metabolic dysfunction.